Welcome to our dedicated page for Spruce Biosciences SEC filings (Ticker: SPRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a 200-page biotech filing packed with pharmacokinetic tables and dilution math is no small task, especially when Spruce Biosciences’ clinical updates can move the stock overnight. If you have ever asked, "How do I find Spruce Biosciences insider trading Form 4 transactions?" or struggled to decode a trial-heavy 10-K, you know the challenge. Our platform tackles that complexity head-on by pairing every new document with AI-powered summaries that spotlight trial milestones, cash runway, and potential dilution.
Whether you need a Spruce Biosciences quarterly earnings report 10-Q filing or an 8-K describing fresh Phase 2 data, Stock Titan delivers real-time filing updates straight from EDGAR. The moment a director buys shares, our alert shows the Spruce Biosciences Form 4 insider transactions real-time. Questions like "understanding Spruce Biosciences SEC documents with AI" or "Spruce Biosciences annual report 10-K simplified" are answered automatically, transforming raw PDFs into plain-English insights. You can quickly jump to sections on development expenses, royalty obligations, or that critical risk factor about trial enrollment.
Use cases extend beyond basic compliance. Monitor Spruce Biosciences executive stock transactions Form 4 before material announcements, compare R&D spend across quarters with our Spruce Biosciences earnings report filing analysis, or review the Spruce Biosciences proxy statement executive compensation to understand incentive alignment. A concise list of resources always sits beside the latest uploads:
- Spruce Biosciences 8-K material events explained
- Every S-3 share offering decoded
- Complete historical database of insider trades
Complex filings, explained simply—so you can focus on whether tildacerfont’s next trial will move the needle.
Spruce Biosciences (SPRB) reported Q3 2025 results marked by tighter spending, liquidity strain, and key program milestones. The company posted a net loss of $8.2 million for the quarter and $24.3 million year‑to‑date, with no collaboration revenue recognized in 2025. Operating expenses fell to $8.2 million in Q3 (from $10.0 million a year ago) as R&D declined on program discontinuations and a 55% workforce reduction, partly offset by increased TA‑ERT manufacturing.
Cash and cash equivalents were $10.7 million at September 30, 2025, and the filing states “substantial doubt” about the ability to continue as a going concern. After quarter‑end, Spruce raised approximately $50.0 million in gross proceeds via a private placement and subsequently terminated and repaid its SVB term loan, including the $0.3 million supplemental final payment. The company effected a 1‑for‑75 reverse stock split and relisted on Nasdaq. Development shifted to tralesinidase alfa (TA‑ERT) for MPS IIIB, which received FDA Breakthrough Therapy designation in October 2025, with a planned BLA submission in the first quarter of 2026.
Spruce Biosciences, Inc. filed an S-3 registering up to 735,325 shares for resale by selling stockholders, consisting of 502,181 outstanding shares and 233,144 shares issuable upon exercise of pre-funded warrants. The company will not receive proceeds from stockholder sales; it would receive only the $0.01 per share exercise price if any pre-funded warrants are exercised for cash.
The shares relate to a private placement that closed on October 9, 2025. The resale may occur from time to time in public or private transactions at market or negotiated prices as described under “Plan of Distribution.” Including two holder examples shown: ExodusPoint Partners Master Fund, LP 144,580; Citadel CEMF Investments Ltd. 110,000. Shares outstanding were 1,065,672 as of October 10, 2025.
The pre-funded warrants are exercisable at any time, subject to a beneficial ownership limitation of 4.99% or 9.99% (holder election), with a maximum increase upon 60 days’ notice, not above 19.99%.
Spruce Biosciences, Inc. filed an S-3 shelf registration to offer up to $300,000,000 of common stock, preferred stock, debt securities, and warrants, to be sold from time to time in one or more offerings. Terms and amounts for any specific sale will be set in a future prospectus supplement.
The company may sell securities directly, through agents, to/through underwriters or dealers, and may use at-the-market offerings. Net proceeds, if any, will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures. Spruce’s common stock trades on the Nasdaq Capital Market under “SPRB”; the last reported price was $124.51 on October 28, 2025.
Spruce completed a one-for-seventy-five reverse stock split effective August 4, 2025; share counts in the prospectus reflect this, including approximately 563,042 shares outstanding as of December 31, 2024.
Spruce Biosciences (SPRB) reported an insider equity event for its President and CFO, Samir Gharib. A performance-based award of 2,053 RSUs granted on March 14, 2024 vested on October 20, 2025 after the board certified performance goals. To cover taxes, 661 shares were withheld at $148.16, resulting in a net issuance of 1,392 shares.
Following these transactions, the officer beneficially owns 6,066 shares, held directly. Each RSU represents the right to receive one share of SPRB common stock upon vesting.
Spruce Biosciences (SPRB) reported an insider equity event by its Chief Executive Officer and director. On 10/20/2025, the Board certified performance goals, causing 4,784 performance‑based RSUs granted on March 14, 2024 to vest. Each RSU represents the right to receive one share of SPRB common stock.
In connection with the vesting, 1,539 shares were withheld for taxes at a price of $148.16, resulting in a net issuance of 3,245 shares. Following these transactions, the reporting person directly beneficially owned 9,474 shares. The Form 4 reflects an “M” code for settlement of RSUs into common stock at $0 and an “F” code for tax withholding.
Spruce Biosciences announced that director Bali Muralidhar, Ph.D. resigned from the board and the compensation committee, effective October 15, 2025. The company stated his departure was not due to any disagreement regarding operations, policies, or practices. This is a governance update with no operational or financial changes disclosed.
Spruce Biosciences (SPRB) — Form 4 insider trading update. Parkman Healthcare Partners LLC and Gregory Martinez reported trades on 10/06/2025 as indirect owners. They purchased 256 shares of common stock at a weighted average price of $17.9108 (within $17.55–$18.00), then sold 232 shares at $19.3264 (within $19.125–$19.63) and sold 25 shares at $17.4557 (within $17.44–$17.56). Following the reported transactions, they beneficially owned 1,050 shares indirectly through private funds. Each reporting person disclaims beneficial ownership beyond pecuniary interest.
Spruce Biosciences (SPRB): Initial insider ownership reported. A Form 3 discloses indirect beneficial ownership of 1,051 shares of common stock. The reporting person is identified as a Director and indicates the shares are held through private funds, with beneficial ownership disclaimed beyond any pecuniary interest.
The filing notes it is made by more than one reporting person, and includes a remark that these securities are also indirectly beneficially owned by Gregory Martinez.
HealthCap VIII amended its Schedule 13D for Spruce Biosciences, Inc. (SPRB) to report current holdings and a recent sale. The filing shows the reporting persons beneficially owned 36,640 shares, equal to
On
FAQ
What is the current stock price of Spruce Biosciences (SPRB)?
What is the market cap of Spruce Biosciences (SPRB)?
